Reducing radiation therapy for head and neck cancer patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This randomized, multicenter trial investigates whether postoperative radiotherapy can be safely reduced by eliminating radiation to the elective neck in patients with squamous cell carcinoma of the head and neck. The study will compare two groups: one receiving standard radiation treatment and another receiving targeted radiation to the primary tumor and affected lymph nodes only. The goal is to minimize long-term side effects while maintaining effective cancer control. The trial will proceed in two phases, with the first phase focusing on the rate of dependence on feeding tubes and the second phase assessing locoregional control rates.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Histologically proven squamous cell carcinoma of the oral cavity/larynx/oro-or hypopharynx (except glottis cancer (pT1/2pN0))
2. Surgery of primary tumor and neck dissection performed according to predefined surgical standard
3. Indication for postoperative radio(chemo)therapy
4. No lymph node metastases \> 6cm
5. Lymph node metastases in not more than 3 lymph node level
6. No distant metastases (cM0)
7. Age ≥ 18 years, no upper age limit
8. Eastern Cooperative Oncology Group (ECOG) ≤ 2
9. Patients who understood protocol contents and are able to behave according to protocol
10. Signed study-specific consent form prior to therapy
11. Start of radiotherapy at least 6 weeks after last tumor-specific surgery (e.g. resection primary tumor, neck dissection, excluded are surgeries according to wound healing complications)

Exclusion Criteria:

1. macroscopic incomplete resection R2
2. Distant metastases (cM1)
3. Radiologically or histologically proven early recurrence after surgery (time frame from surgery to start of radio(chemo)therapy)
4. Lymph node metastases in \> 3 lymph node level
5. pregnant or lactating/nursing women
6. fertile patients that are not willing to use highly effective methods of contraception (per institutional standards) during treatment
7. Any condition potentially hampering compliance with the study protocol and follow-up schedule
8. On-treatment participation on other clinical therapeutic trials
9. Prior tumor-specific therapy any other than surgery (like prior radiotherapy in the head and neck region, prior chemo- or immunotherapy (neoadjuvant/induction))
10. Patients who have contraindication for MRI and CT with contrast agent (both)
11. Prior (\> 2 months before beginning of radio(chemo)therapy) neck dissection or surgery in the head and neck area affecting lymph drainage
12. History of another primary malignancy except for malignancy treated with curative intent and with no known active disease ≥5 years before diagnosis of head and neck cancer, adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease, adequately treated carcinoma in situ without evidence of disease

Where it's running

• Universitätsklinikum Erlangen, Strahlenklinik
  Erlangen, Bavaria, Germany Recruiting

Study contacts

• Principal investigator: Rainer Fietkau, Prof — Universitätsklinikum Erlangen, Radiation Oncology
• Study coordinator: Marlen Haderlein, PD
• Email: marlen.haderlein@uk-erlangen.de
• Phone: +49913185

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Platform for studying biomarkers and treatments in head and neck cancer

  This study is trying to gather information on how well different treatments work for people with advanced head and neck cancer to help improve future care.

  Recruiting AIO-Studien-gGmbH · Essen and 1 other locations · NCT06380686

• Fluorescence-guided surgery to help remove laryngeal and hypopharyngeal cancers

  This trial tests a fluorescent imaging agent to help see cancer tissue during laryngeal and hypopharyngeal cancer surgery in adults.

  Recruiting Phase 2 Erasmus Medical Center · Rotterdam, South Holland and 1 other locations · NCT05752149

• Immune biomarker testing in cisplatin-ineligible head and neck squamous cell cancer patients treated with chemoradiation and docetaxel

  This project will test whether immune markers from tumor tissue, blood, saliva and stool can help predict outcomes and show increased tumor immune activity in people with oropharynx, hypopharynx, larynx or oral cavity squamous cell cancer who can't take cisplatin and are receiving chemoradiation with docetaxel.

  Recruiting University of Erlangen-Nürnberg Medical School · Erlangen, Bavaria · NCT06947668

• Treatment for advanced laryngeal and hypopharyngeal cancer using chemotherapy and immunotherapy

  This study is testing if adding an immune therapy to chemotherapy can help people with advanced throat cancer keep their voice box while improving their chances of survival.

  Recruiting at 5 sites Phase 2 University of Leipzig · Mannheim, Baden-Würtemberg and 8 other locations · NCT06137378

• Finding tissue and blood markers that predict response to immunotherapy in recurrent or metastatic upper throat and mouth squamous cell cancer

  This project will try to find tumor and blood markers that predict whether adults with recurrent or metastatic squamous cell cancer of the oropharynx or nearby upper aerodigestive sites will respond to PD‑1 immunotherapy.

  Recruiting at 2 sites Fondation Hôpital Saint-Joseph · Paris and 2 other locations · NCT06061705

• Lower dose radiation therapy for HPV positive head and neck cancer

  This study is testing if a lower dose of radiation therapy can safely treat HPV positive head and neck cancer while causing fewer side effects.

  Recruiting at 3 sites Phase 2 University of Virginia · Miami, Florida and 4 other locations · NCT05962242

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.